Oncolytics Financial Statements From 2010 to 2024

ONC Stock  CAD 1.46  0.02  1.39%   
Oncolytics Biotech financial statements provide useful quarterly and yearly information to potential Oncolytics Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Oncolytics Biotech financial statements helps investors assess Oncolytics Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Oncolytics Biotech's valuation are summarized below:
Market Capitalization
110.1 M
Earnings Share
(0.41)
We have found one hundred twenty available trending fundamental ratios for Oncolytics Biotech, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to check out Oncolytics Biotech's recent fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 23rd of April 2024, Market Cap is likely to grow to about 132.4 M. Also, Enterprise Value is likely to grow to about 113.3 M
Check Oncolytics Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncolytics main balance sheet or income statement drivers, such as Depreciation And Amortization of 864.6 K, Interest Expense of 637.6 K or Selling General Administrative of 16.5 M, as well as many exotic indicators such as Price To Sales Ratio of 68.55, Dividend Yield of 0.0 or PTB Ratio of 4.61. Oncolytics financial statements analysis is a perfect complement when working with Oncolytics Biotech Valuation or Volatility modules.
  
This module can also supplement various Oncolytics Biotech Technical models . Check out the analysis of Oncolytics Biotech Correlation against competitors.
To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.

Oncolytics Biotech Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets30.4 M38.8 M26.2 M
Slightly volatile
Short and Long Term Debt Total287.5 K428.9 K456.8 K
Very volatile
Total Current Liabilities3.9 M4.2 M4.6 M
Very volatile
Property Plant And Equipment Net460.3 K647 K498.4 K
Slightly volatile
Accounts PayableM1.1 M3.2 M
Slightly volatile
Cash19.4 M34.9 M20.7 M
Pretty Stable
Non Current Assets Total614.6 K647 K746 K
Very volatile
Cash And Short Term Investments26 M37 M23.4 M
Slightly volatile
Net Receivables470 K599.1 K685.6 K
Pretty Stable
Common Stock Shares Outstanding78.1 M74.4 M27.7 M
Slightly volatile
Liabilities And Stockholders Equity29.9 M42.9 M26.4 M
Slightly volatile
Other Current Assets3.7 M3.5 M1.4 M
Slightly volatile
Other Stockholder Equity48.8 M36 M42 M
Pretty Stable
Total LiabilitiesM11.3 M7.7 M
Slightly volatile
Property Plant And Equipment Gross1.4 M1.3 M608 K
Slightly volatile
Total Current Assets27.9 M38.2 M25.3 M
Slightly volatile
Intangible Assets154.5 K162.7 K336.5 K
Slightly volatile
Other Assets1.2 M1.1 M955.3 K
Slightly volatile
Common Stock Total Equity294.9 M410.3 M281.9 M
Slightly volatile
Common Stock320.8 M464.6 M292.7 M
Slightly volatile
Property Plant Equipment610.4 K749.8 K567.1 K
Slightly volatile
Capital Surpluse35.9 M46.1 M31.6 M
Slightly volatile
Cash And Equivalents14.1 M13.4 M3.9 M
Slightly volatile
Other Liabilities6.9 M7.7 M5.6 M
Slightly volatile
Current Deferred Revenue989.2 K834.7 K1.3 M
Slightly volatile
Non Current Liabilities Other44.8 K47.2 K2.5 M
Slightly volatile
Net Working Capital26.6 M33.9 M18.9 M
Slightly volatile
Capital Stock399.6 M430.9 M324 M
Slightly volatile
Capital Lease Obligations377.5 K423 K486.2 K
Slightly volatile

Oncolytics Biotech Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative16.5 M15.7 MM
Slightly volatile
Other Operating Expenses19 M31 M21.6 M
Pretty Stable
Research Development12.6 M17.7 M13.7 M
Very volatile
Total Operating Expenses18.7 M33.8 M21.1 M
Slightly volatile
Interest Income1.8 M1.3 M1.2 M
Pretty Stable
Net Interest Income1.4 M1.3 M339.8 K
Slightly volatile
Reconciled Depreciation371.6 K403 K224.8 K
Slightly volatile

Oncolytics Biotech Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow17.8 M11.7 M20.6 M
Very volatile
Depreciation299.9 K403 K233.7 K
Slightly volatile
Capital Expenditures7.6 KK103.6 K
Slightly volatile
Total Cash From Financing Activities18.8 M32 M19.2 M
Slightly volatile
End Period Cash Flow19.4 M34.9 M20.7 M
Pretty Stable
Stock Based Compensation1.6 M2.1 M1.4 M
Slightly volatile
Sale Purchase Of Stock10.3 K10.8 K12.4 M
Slightly volatile
Issuance Of Capital Stock26.9 M31.6 M18.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio68.5572.163.8 M
Slightly volatile
Days Sales Outstanding3.73.8914.0234
Slightly volatile
Average Payables254.7 K268.1 K2.5 M
Slightly volatile
Stock Based Compensation To Revenue0.170.15060.1536
Slightly volatile
EV To Sales64.267.583.5 M
Slightly volatile
Inventory Turnover127142155
Slightly volatile
Days Of Inventory On Hand1.852.082.2607
Slightly volatile
Payables Turnover0.350.372588.1336
Very volatile
Sales General And Administrative To Revenue0.120.140.1479
Slightly volatile
Average Inventory13.1 K13.7 K37.7 K
Slightly volatile
Research And Ddevelopement To Revenue13.117.447.3417
Very volatile
Cash Per Share0.490.51631.9792
Slightly volatile
Capex To Operating Cash Flow3.0E-43.0E-40.0076
Slightly volatile
Days Payables Outstanding548980385
Slightly volatile
Net Current Asset Value25.5 M28.7 M31.3 M
Slightly volatile
Income Quality0.711.02510.8951
Pretty Stable
Tangible Asset Value26.3 M29.6 M32.2 M
Slightly volatile
Intangibles To Total Assets0.01410.01490.0361
Slightly volatile
Net Debt To EBITDA1.570.93181.5125
Slightly volatile
Current Ratio13.959.009410.3926
Pretty Stable
Receivables Turnover10297.0899.557
Slightly volatile
Graham Number1.841.946.5987
Slightly volatile
Graham Net Net0.330.351.5523
Slightly volatile
Average Receivables655.4 K624.2 K528.6 K
Slightly volatile
Revenue Per Share0.570.550.5592
Slightly volatile
Days Of Payables Outstanding548980385
Slightly volatile
Ebt Per Ebit0.80.81840.9804
Very volatile
Long Term Debt To Capitalization0.00990.01041.7102
Slightly volatile
Quick Ratio14.228.243310.934
Pretty Stable
Dividend Paid And Capex Coverage Ratio241382349
Slightly volatile
Net Income Per E B T0.811.00351.005
Very volatile
Cash Ratio9.477.44259.0482
Slightly volatile
Days Of Inventory Outstanding1.852.082.2607
Slightly volatile
Days Of Sales Outstanding3.73.8914.0234
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00031.0162
Pretty Stable
Fixed Asset Turnover11.210.6710.9418
Slightly volatile
Capital Expenditure Coverage Ratio241382349
Slightly volatile
Price Sales Ratio68.5572.163.8 M
Slightly volatile
Asset Turnover0.210.20.2031
Slightly volatile
Operating Cycle2.73.053.3161
Slightly volatile

Oncolytics Biotech Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap132.4 M121 M108 M
Very volatile
Working Capital25.5 M28.7 M31.3 M
Slightly volatile
Enterprise Value113.3 M89.9 M87.3 M
Pretty Stable

About Oncolytics Biotech Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Oncolytics Biotech income statement, its balance sheet, and the statement of cash flows. Oncolytics Biotech investors use historical funamental indicators, such as Oncolytics Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Oncolytics Biotech investors may use each financial statement separately, they are all related. The changes in Oncolytics Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Oncolytics Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Oncolytics Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Oncolytics Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue834.7 K989.2 K
Total Revenue 0.00  0.00 
Cost Of Revenue 0.00  0.00 
Stock Based Compensation To Revenue 0.15  0.17 
Sales General And Administrative To Revenue 0.14  0.12 
Research And Ddevelopement To Revenue 7.44  13.11 
Capex To Revenue(0.02)(0.02)
Revenue Per Share 0.55  0.57 
Ebit Per Revenue(6.81)(7.15)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Oncolytics Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Oncolytics Biotech's short interest history, or implied volatility extrapolated from Oncolytics Biotech options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Oncolytics Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncolytics Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncolytics Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncolytics Biotech Stock:
Check out the analysis of Oncolytics Biotech Correlation against competitors.
To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.
Note that the Oncolytics Biotech information on this page should be used as a complementary analysis to other Oncolytics Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Oncolytics Stock analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Commodity Directory
Find actively traded commodities issued by global exchanges
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.